Abstract
Aim
The goal of the present study was to prospectively assess the long-term clinical outcome of biologic modifying drug therapy in a population of Saudi rheumatoid arthritis (RA) patients.
Patients and methods
This is the first prospective, long-term report on the efficacy and safety of biologic therapy in Saudi RA patients. It is a single center, observational study with a follow-up period of 3 years. Enrolled were 120 biologic naïve patients (94 women, 78.3 %; mean age 48.4 ± 17.9 years, mean disease duration 7.3 ± 3.9 years) with the diagnosis of RA (ACR/EULAR, 2010 criteria) who were inadequate responders to methotrexate and synthetic DMARDs.
Results
After 3 years, the mean Disease Activity Index-28 (DAS-28), Health Assessment Questionnaire (HAQ), Pain Score, ESR, and CRP values improved significantly. Of the 99 patients completing the 3-year follow-up, 35.3 % of patients achieved DAS-28 remission and 53.5 % achieved low disease activity, and 11.1 % of patients had moderate to high activity scores. At the 3-year follow-up, 80 % of patients had no evidence of significant radiographic progression (achieved < 0.5 of the mean total Sharp score). Infections were reported in 11.7 % and significantly correlated with conjugate use of oral prednisolone at doses above 5 mg/day, with chest infections being the most common type of infection (6.7 %).
Conclusion
The results of this study can be understood as real-life clinical experience displaying the incremental benefit of biologic therapy in refractory disease when it is added to other optimal strategies. The study showed satisfying clinical and functional benefit with considerable safety.
Zusammenfassung
Ziel
Ziel der vorliegenden Studie war die prospektive Untersuchung des klinischen Langzeitverlaufs unter biologischer krankheitsmodifizierender medikamentöser Therapie in einer Population von saudischen Patienten mit rheumatoider Arthritis (RA).
Patienten und Methoden
Dies ist die erste prospektive Langzeitstudie zur Wirksamkeit und Sicherheit der biologischen Therapie bei saudischen RA-Patienten. Es handelt sich um eine Einzelzentrum-Beobachtungsstudie über 3 Jahre. In die Studie eingeschlossen wurden 120 Biologika-naive Patienten (94 Frauen, 78,3 %; Durchschnittsalter: 48,4 ± 17,9 Jahre, durchschnittliche Krankheitsdauer: 7,3 ± 3,9 Jahre) mit der Diagnose einer RA (ACR/EULAR-Kriterien von 2010), die nicht ausreichend auf Methotrexat und synthetische DMARD ansprachen.
Ergebnisse
Nach 3 Jahren besserten sich die Durchschnittswerte für den Disease Activity Score 28 (DAS-28), Health Assessment Questionnaire, Schmerzscore, BSG und CRP deutlich. Beim DAS-28 erzielten von den 99 Patienten mit vollständiger 3-jähriger Nachbeobachtung 35,3 % eine Remission, 53,5 % eine niedrige Krankheitsaktivität und 11,1 % einen mittleren bis hohen Wert. Nach 3 Jahren Follow-up bestand bei 80 % der Patienten kein Hinweis auf eine wesentliche röntgenologische Progression (< 0,5 des durchschnittlichen Sharp-Gesamtscores). Infektionen wurden in 11,7 % der Fälle dokumentiert, sie waren signifikant mit der kombinierten Gabe von Prednisolon p.o. in Dosen über 5 mg/ korreliert, am häufigsten (6,7 %) waren Thoraxinfektionen.
Schlussfolgerung
Die Ergebnisse der vorliegenden Studie können als praktische klinische Erfahrung angesehen werden, welche den zunehmenden Nutzen der biologischen Therapie bei therapierefraktärer Erkrankung zeigt, wenn sie optimal mit anderen Strategien zusammen eingesetzt wird; die Studie ergab einen befriedigenden klinischen und funktionellen Nutzen bei beträchtlicher Sicherheit.
Similar content being viewed by others
References
Burmester G-R, Pratt AG, Scherer HU, Van-Laar JM (2012) Rheumatoid arthritis: pathogenesis and clinical features. In: Bijlsma JWJ (ed) EULAR textbook on rheumatic diseases. 1st edn., BMJ Publications, London. Chapter 9. pp 206–231
Wolfe F, Michaud K (2010) The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study. Arthritis Res Ther 12:R35
Gaujoux-Viala C, Smolen JS, Landewé R et al (2010) Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying anti-rheumatic drugs: systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69:1004–1009
Scott DL, Kingsley GH (2006) Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 355:704–712
Klareskog L, Heijde D van der, Jager JP de et al (2004) TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators: therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363:675–681
Breedveld FC, Weisman MH, Kavanaugh AF et al (2006) The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26–37
Van de Putte LB, Atkins C, Malaise M et al (2004) Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 63:508–516
Keystone EC, Kavanaugh AF, Sharp JT et al (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo controlled, 52-week trial. Arthritis Rheum 50:1400–1411
Weinblatt ME, Keystone EC, Furst DE et al (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48:35–45
Maini R, St Clair EW, Breedveld F et al (1999) Infliximab (chimeric antitumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. ATTRACT Study Group. Lancet 354:1932–1939
Van der Heijde DM, Hof MA van’t, Riel PL van et al (1992) Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 51:177–181
Felson DT, Anderson JJ, Boers M et al (1995) American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38:727–735
Aletaha D, Smolen J, Ward MM (2006) Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis Rheum 54:2784–2792
Aletaha D, Neogi T, Silman A et al (2010) 2010 Rheumatoid arthritis classification criteria an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569–2581
Heijde D van der, Dankert T, Nieman F et al (1999) Reliability and sensitivity to change of a simplification of the Sharp/van der Heijde radiological assessment in rheumatoid arthritis. Rheum (Oxford) 38:941–947
Pincus T, Yazici Y, Sokka T et al (2003) Methotrexate as the “anchor drug” for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 21(31):S178–S185
Salliot C, Heijde D van der (2009) Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 68:1100–1104
Lipsky PE (1994) Harrison’s principles of internal medicine. In: Isselbacher KJ, Braunwald E, Fauci AS et al (eds) Rheumatoid arthritis, 17th edn. McGraw-Hill, New York, pp 1648–1655
Gremese E, Salaffi F, Bosello SL et al (2013) Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study (VERA). Ann Rheum Dis 72(6):858–862. doi:10.1136/annrheumdis-2012-201456
Weinblatt ME, Keystone EC, Cohen MD et al (2011) Factors associated with radiographic progression in patients with rheumatoid arthritis who were treated with methotrexate. J Rheumatol 38(2):242–246
St Clair EW, Heijde DM van der, Smolen JS et al (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50:3432–3443
Donahue KE, Gartlehner G, Jonas DE et al (2008) Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 148:124–134
Rau R, Herborn G, Menninger H, Sangha O (2002) Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a one-year double blind study in 174 patients. Rheum (Oxford) 41:196–204
Weinblatt ME, Reda D, Henderson W et al (1999) Sulfasalazine treatment for rheumatoid arthritis: a metaanalysis of 15 randomized trials. J Rheumatol 26:2123–2130
Nam JL, Winthrop K, Vollenhoven R van et al (2010) Current evidence for the management of rheumatoid arthritis with biological disease modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 69:976–986
Gorter SL, Bijlsma H, Cutolo M et al (2010) Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 69:1010–1014. 65
Hamilton J, McInnes IB, Suarez-Almazor ME et al (2000) Antimalarials for treating rheumatoid arthritis. Cochrane Database Syst Rev 4
O’Dell JR, Haire CE, Erikson N et al (1996) Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 334:1287–1291
Calgüneri M, Pay S, Caliskaner Z et al (1999) Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis. Clin Exp Rheumatol 17:699–704
Van der Heijde DM, Riel PL van, Nuver-Zwart IH, Putte LB van de (1990) Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year followup. Lancet 335:539
Sokka T, Kautiainen H, Möttönen T, Hannonen P (1999) Work disability in rheumatoid arthritis 10 years after the diagnosis. J Rheumatol 26(8):1681–1685
Sokka T, Häkkinen A, Kautiainen H et al (2008) Physical inactivity in patients with rheumatoid arthritis: data from twenty-one countries in a cross-sectional, international study. Arthritis Rheum 59(1):42–50
Black N (1996) Why we need observational studies to evaluate the effectiveness of health care. BMJ 312:1215–1218
Rothwell PM (2005) External validity of randomised controlled trials: “to whom do the results of this trial apply?” Lancet 365:82–93
Ware JE, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). Conceptual framework and item selection. Med Care 30:473–483
Klareskog L, Heijde D van der, Jager JP de et al (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363:675–681
Maini RN, Breedveld FC, Kalden JR et al (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552–1563
Edwards JC, Szczepanski L, Szechinski J et al (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572–2581
Grijalva CJ, Chen L, Delzell E et al (2011) Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 306(21):2331–2339
Strangfeld A, Eveslage M, Schneider M et al (2011) Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 70(11):1914–1920
Acknowledgment
The authors would like to acknowledge the great effort and contribution of Professor Dr. Yusuf Yazici (Associate Professor of Rheumatology, NYU) in reviewing the scientific and statistical contents of this research.
Compliance with ethical guidelines
Conflict of interest. R.H.A. Mohammed, H.H. Kewan, and M. Bukhari state that there are no conflicts of interest.
All studies on humans described in the present manuscript were carried out with the approval of the responsible ethics committee and in accordance with national law and the Helsinki Declaration of 1975 (in its current, revised form). Informed consent was obtained from all patients included in studies.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mohammed, R., Kewan, H. & Bukhari, M. Assessment of the treat-to-target strategy in patients with refractory rheumatoid arthritis. Z. Rheumatol. 73, 746–753 (2014). https://doi.org/10.1007/s00393-013-1335-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00393-013-1335-2